Akili is developing video game-based digital medicine to improve cognitive function. The company uses features of the tech and entertainment industries to develop it's digital treatment and address inattention in children with attention deficit hyperactivity disorder.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/26/2021 | Series D | $151.68MM | $xx.xx | $452.34MM | Amgen Ventures, Baillie Gifford, Dave Baszucki, Evidity Health Capital, Fearless Ventures, Jazz Venture Partners, Ladera Venture Partners, Mirae Assets, M Ventures, Neuberger Berman Funds, New Leaf Venture Partners, Omidyar Technology Ventures, Polaris Partners, Quad Investment Management, Shionogi & Co Ltd, Temasek | |
Price per Share
$xx.xx
Shares Outstanding
18,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.5x
Conversion Ratio
1.0x
Dividend Rate
10.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Amgen Ventures, Baillie Gifford, Dave Baszucki, Evidity Health Capital, Fearless Ventures, Jazz Venture Partners, Ladera Venture Partners, Mirae Assets, M Ventures, Neuberger Berman Funds, New Leaf Venture Partners, Omidyar Technology Ventures, Polaris Partners, Quad Investment Management, Shionogi & Co Ltd, Temasek
|
||||||
05/09/2018 | Series C | $68.2MM | $xx.xx | $259.42MM | Amgen Ventures, Canepa Advanced Healthcare Fund Brooklands Capital Strategies, Clsa, Digital Garage Group, Fearless Ventures, Jazz Venture Partners, M Ventures, Omidyar Technology Ventures, Temasek | |
Price per Share
$xx.xx
Shares Outstanding
8,016,645
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amgen Ventures, Canepa Advanced Healthcare Fund Brooklands Capital Strategies, Clsa, Digital Garage Group, Fearless Ventures, Jazz Venture Partners, M Ventures, Omidyar Technology Ventures, Temasek
|
||||||
07/20/2016 | Series B | $42.36MM | $xx.xx | $113.73MM | Amgen Ventures, M Ventures | |
Price per Share
$xx.xx
Shares Outstanding
7,341,485
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amgen Ventures, M Ventures
|
||||||
02/19/2012 | Series A-1 | $4MM | $xx.xx | $28.02MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
4,000,000
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
02/19/2012 | Series A-2 | $8.83MM | $xx.xx | $28.02MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
4,427,072
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|